Compare EVAX & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | CXAI |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 27.8M |
| IPO Year | 2020 | 2020 |
| Metric | EVAX | CXAI |
|---|---|---|
| Price | $3.25 | $2.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | 50.5K | ★ 100.9K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $4,583,000.00 |
| Revenue This Year | N/A | $33.54 |
| Revenue Next Year | $328.20 | $116.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.77 | $0.09 |
| 52 Week High | $12.15 | $4.88 |
| Indicator | EVAX | CXAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 48.25 |
| Support Level | $2.92 | $2.39 |
| Resistance Level | $3.33 | $4.88 |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 87.14 | 11.43 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.